Gavin MacBeath
2023
In 2023, Gavin MacBeath earned a total compensation of $3.2M as Chief Executive Officer and Director at TScan Therapeutics, a 135% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $296,000 |
|---|---|
| Option Awards | $2,342,541 |
| Salary | $545,121 |
| Other | $12,392 |
| Total | $3,196,054 |
MacBeath received $2.3M in option awards, accounting for 73% of the total pay in 2023.
MacBeath also received $296K in non-equity incentive plan, $545.1K in salary and $12.4K in other compensation.
Rankings
In 2023, Gavin MacBeath's compensation ranked 273rd out of 2,983 executives tracked by ExecPay. In other words, MacBeath earned more than 90.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 273 out of 2,983 | 91st |
Division Manufacturing | 147 out of 1,637 | 91st |
Major group Chemicals And Allied Products | 100 out of 906 | 89th |
Industry group Drugs | 97 out of 869 | 89th |
Industry Biological Products, Except Diagnostic Substances | 34 out of 211 | 84th |
Source: SEC filing on April 30, 2024.
MacBeath's colleagues
We found four more compensation records of executives who worked with Gavin MacBeath at TScan Therapeutics in 2023.